Bioequivalence Study of Two Formulations With the Association of Tenofovir 300 mg and Emtricitabine 200 mg.

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
Objective: To evaluate the relative bioavailability of a new formulation containing a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg (T) and compare this formulation with the branded formulation (R) to meet regulatory criteria for marketing the test product in Argentina.
Epistemonikos ID: 998fe1f6d24ea5f3baf01bb15458bf35236a05fc
First added on: May 12, 2024